Zealand Pharma A/S (OTCMKTS:ZLDPF) Downgraded by Zacks Research to Hold

Zacks Research cut shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) from a strong-buy rating to a hold rating in a research report sent to investors on Tuesday morning,Zacks reports.

A number of other research analysts have also issued reports on ZLDPF. Barclays lowered shares of Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 8th. Jefferies Financial Group lowered Zealand Pharma A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, July 13th. Finally, Wells Fargo & Company reissued an “overweight” rating on shares of Zealand Pharma A/S in a research report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, Zealand Pharma A/S has an average rating of “Hold”.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $36.75 on Tuesday. The business’s 50 day moving average is $38.85 and its two-hundred day moving average is $46.81. The company has a quick ratio of 13.98, a current ratio of 13.98 and a debt-to-equity ratio of 0.02. Zealand Pharma A/S has a 12 month low of $33.08 and a 12 month high of $83.12. The company has a market cap of $2.63 billion, a PE ratio of 6.09 and a beta of 0.99.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a biotechnology company headquartered in Copenhagen, Denmark. Founded in 1998, it discovers and develops peptide-based medicines, with a focus on metabolic diseases and rare conditions. The company’s portfolio has included Zegalogue (dasiglucagon), an injectable treatment approved in the United States for severe hypoglycemia in people with diabetes. Zealand also develops investigational medicines for areas such as obesity, liver disease and rare gastrointestinal disorders, and works with pharmaceutical partners to advance and commercialize selected programs.